906 related articles for article (PubMed ID: 15713943)
1. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
2. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
5. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
8. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of aspirin to prevent colorectal adenomas.
Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
[TBL] [Abstract][Full Text] [Related]
12. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.
Baron JA; Sandler RS; Bresalier RS; Lanas A; Morton DG; Riddell R; Iverson ER; Demets DL
Lancet; 2008 Nov; 372(9651):1756-64. PubMed ID: 18922570
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
16. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Bottone FG; Barry WT
Curr Med Res Opin; 2009 Jun; 25(6):1535-50. PubMed ID: 19453292
[TBL] [Abstract][Full Text] [Related]
18. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
19. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Bijlsma JW
Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
[TBL] [Abstract][Full Text] [Related]
20. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
